An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Carotuximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors TRACON Pharmaceuticals
- 08 Aug 2017 According to a Tracon Pharmaceuticals media release, company expects to report initial data in the first half of 2018.
- 18 May 2016 According to a Tracon Pharmaceuticals media release, dosing has been initiated in this trial and topline data are anticipated in 2017.
- 11 May 2016 According to a TRACON Pharmaceuticals media release, the company expects to initiate dosing in this trial in the second quarter of 2016.